Providence Cancer Center at Providence Portland Medical Center

Summary

Providence Cancer Center at Providence Portland Medical Center is a medical facility located in Portland, Oregon. This center is recognized for care of Breast Cancer, Lung Cancer, Solid Tumors, Pancreatic Cancer, Cancer and other specialties. Providence Cancer Center at Providence Portland Medical Center is involved with conducting 165 clinical trials across 253 conditions. There are 9 research doctors associated with this hospital, such as Rachel Sanborn, MD, Matthew Taylor, MD, Rom S. Leidner, MD, and Brendan D. Curti, MD.

Top PIs

Clinical Trials running at Providence Cancer Center at Providence Portland Medical Center

Breast Cancer

Lung Cancer

Ovarian Cancer

Solid Tumors

Cancer

Non-Hodgkin's Lymphoma

Squamous Cell Carcinoma

Pancreatic Cancer

Colorectal Cancer

Non-Small Cell Lung Cancer

PF-07220060 + Letrozole

for Breast Cancer

The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

Recruiting

2 awards

Phase 3

4 criteria

Elacestrant

for Breast Cancer

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

Recruiting

2 awards

Phase 3

3 criteria

SGN-B6A

for Cancer

This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.

Recruiting

1 award

Phase 1